Bortezomib, lenalidomide, and dexamethasone versus bortezomib, doxorubicin, and dexamethasone in newly diagnosed multiple myeloma.
Humans
Multiple Myeloma
/ drug therapy
Bortezomib
/ therapeutic use
Dexamethasone
/ therapeutic use
Lenalidomide
/ therapeutic use
Doxorubicin
/ therapeutic use
Middle Aged
Antineoplastic Combined Chemotherapy Protocols
/ therapeutic use
Female
Male
Aged
Adult
Retrospective Studies
Progression-Free Survival
Aged, 80 and over
And dexamethasone
Bortezomib
Doxorubicin
Lenalidomide
Multiple myeloma
Journal
BMC cancer
ISSN: 1471-2407
Titre abrégé: BMC Cancer
Pays: England
ID NLM: 100967800
Informations de publication
Date de publication:
09 Sep 2024
09 Sep 2024
Historique:
received:
25
03
2024
accepted:
30
08
2024
medline:
10
9
2024
pubmed:
10
9
2024
entrez:
9
9
2024
Statut:
epublish
Résumé
Bortezomib, lenalidomide, and dexamethasone (VRD), and bortezomib, doxorubicin, and dexamethasone (PAD), are commonly used in induction regimens for patients with newly diagnosed multiple myeloma (NDMM) in China. This real-world study enrolled 390 patients, 195 receiving VRD and 195 receiving PAD induction. The primary endpoint was progression-free survival (PFS) and stringent complete remission/complete remission. Across the entire cohort, VRD demonstrated significantly improved five-year overall survival (OS) (74% vs. 59%, p = 0.0024) and five-year PFS (67% vs. 37%, p = 0.0018) compared to PAD. Notably, the median OS and PFS were not reached for VRD-treated patients, while they were 77 months (60-not reached [NR]) and 46 months (36-NR), respectively, for PAD. In patients with standard-risk cytogenetics, VRD showed superior five-year OS (83% vs. 58%, p = 0.0038) and PFS (78% vs. 48%, p = 0.0091) compared to PAD. However, these differences were not statistically significant in high-risk patients. For transplanted patients, VRD was associated with superior five-year OS (91% vs. 67%, p = 0.014) and PFS (79% vs. 47%, p = 0.015) compared to PAD. In non-transplanted patients, VRD showed a trend towards improved five-year OS (p = 0.085) and PFS (p = 0.073) compared to the PAD group. In conclusion, VRD displayed superior OS and PFS outcomes in standard-risk patients and those who underwent transplantation. These findings suggest potential advantages of VRD over PAD in real-world clinical settings for NDMM treatment. However, due to the imbalance in transplantation rates between the VRD and PAD groups, limitations in testing for high-risk cytogenetic abnormalities (HRA), and the difference between the received cycles and salvage therapies, the conclusions of this study should be interpreted with caution.
Identifiants
pubmed: 39251979
doi: 10.1186/s12885-024-12880-9
pii: 10.1186/s12885-024-12880-9
doi:
Substances chimiques
Bortezomib
69G8BD63PP
Dexamethasone
7S5I7G3JQL
Lenalidomide
F0P408N6V4
Doxorubicin
80168379AG
Types de publication
Journal Article
Comparative Study
Langues
eng
Sous-ensembles de citation
IM
Pagination
1123Subventions
Organisme : Yang Liang
ID : 201603
Organisme : Hua Wang
ID : 81700148
Informations de copyright
© 2024. The Author(s).
Références
Cowan AJ, Green DJ, Kwok M, et al. Diagnosis and management of multiple myeloma: a review. JAMA. 2022;327(5):464–77. https://doi.org/10.1001/jama.2022.0003 .
doi: 10.1001/jama.2022.0003
pubmed: 35103762
Joseph NS, Kaufman JL, Dhodapkar MV, et al. Long-term follow-up results of lenalidomide, bortezomib, and dexamethasone induction therapy and risk-adapted maintenance approach in newly diagnosed multiple myeloma. J Clin Oncol. 2020;38(17):1928–37. https://doi.org/10.1200/JCO.19.02515 .
doi: 10.1200/JCO.19.02515
pubmed: 32298201
pmcid: 7587409
Bergsagel DE. Is aggressive chemotherapy more effective in the treatment of plasma cell myeloma? Eur J Cancer Clin Oncol. 1989;25(2):159–61. https://doi.org/10.1016/0277-5379(89)90001-1 .
doi: 10.1016/0277-5379(89)90001-1
pubmed: 2649372
Richardson PG, Weller E, Lonial S, et al. Lenalidomide, bortezomib, and dexamethasone combination therapy in patients with newly diagnosed multiple myeloma. J Am Soc Hematol Blood. 2010;116(5):679–86. https://doi.org/10.1182/blood-2010-02-268862 .
doi: 10.1182/blood-2010-02-268862
Rosiñol L, Oriol A, Rios R, et al. Bortezomib, lenalidomide, and dexamethasone as induction therapy prior to autologous transplant in multiple myeloma. J Am Soc Hematol Blood. 2019;134(16):1337–45. https://doi.org/10.1182/blood.2019000241 .
doi: 10.1182/blood.2019000241
Durie BGM, Hoering A, Sexton R, et al. Longer term follow-up of the randomized phase III trial SWOG S0777: bortezomib, lenalidomide and dexamethasone vs. lenalidomide and dexamethasone in patients (pts) with previously untreated multiple myeloma without an intent for immediate autologous stem cell transplant (ASCT). Blood Cancer J. 2020;10(5):53. https://doi.org/10.1038/s41408-020-0311-8 .
doi: 10.1038/s41408-020-0311-8
pubmed: 32393732
pmcid: 7214419
Durie BGM, Hoering A, Abidi MH, et al. Bortezomib with lenalidomide and dexamethasone versus lenalidomide and dexamethasone alone in patients with newly diagnosed myeloma without intent for immediate autologous stem-cell transplant (SWOG S0777): a randomised, open-label, phase 3 trial. Lancet. 2017;389(10068):519–27. https://doi.org/10.1016/S0140-6736(16)31594-X .
doi: 10.1016/S0140-6736(16)31594-X
pubmed: 28017406
Sonneveld P, Schmidt-Wolf IGH, van der Holt B, et al. Bortezomib induction and maintenance treatment in patients with newly diagnosed multiple myeloma: results of the randomized phase III HOVON-65/GMMG-HD4 trial. J Clin Oncol. 2012;30(24):2946–55. https://doi.org/10.1200/JCO.2011.39.6820 .
doi: 10.1200/JCO.2011.39.6820
pubmed: 22802322
Mai EK, Bertsch U, Dürig J, et al. Phase III trial of bortezomib, cyclophosphamide and dexamethasone (VCD) versus bortezomib, doxorubicin and dexamethasone (PAd) in newly diagnosed myeloma. Leukemia. 2015;29(8):1721–9. https://doi.org/10.1038/leu.2015.80 .
doi: 10.1038/leu.2015.80
pubmed: 25787915
Popat R, Oakervee HE, Hallam S, et al. Bortezomib, doxorubicin and dexamethasone (PAD) frontline treatment of multiple myeloma: updated results after long-term follow‐up. Br J Haematol. 2008;141(4):512–6. https://doi.org/10.1111/j.1365-2141.2008.06997.x .
doi: 10.1111/j.1365-2141.2008.06997.x
pubmed: 18371113
Huang BT, Tan Y, Zhao WH, et al. How to determine bortezomib-based regimen for elderly patients with multiple myeloma: PAD versus CBd, an observational study. J Cancer Res Clin Oncol. 2014;140(2):303–9. https://doi.org/10.1007/s00432-013-1570-6 .
doi: 10.1007/s00432-013-1570-6
pubmed: 24337419
Kumar S, Paiva B, Anderson KC, et al. International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma. Lancet Oncol. 2016;17(8):e328–46. https://doi.org/10.1016/S1470-2045(16)30206-6 .
doi: 10.1016/S1470-2045(16)30206-6
pubmed: 27511158
Costa LJ, Derman BA, Bal S, et al. International harmonization in performing and reporting minimal residual disease assessment in multiple myeloma trials. Leukemia. 2021;35(1):18–30. https://doi.org/10.1038/s41375-020-01012-4 .
doi: 10.1038/s41375-020-01012-4
pubmed: 32778736
Palumbo A, Rajkumar SV, San Miguel JF, et al. International Myeloma Working Group consensus statement for the management, treatment, and supportive care of patients with myeloma not eligible for standard autologous stem-cell transplantation. J Clin Oncol. 2014;32(6):587–600. https://doi.org/10.1200/JCO.2013.48.7934 .
doi: 10.1200/JCO.2013.48.7934
pubmed: 24419113
pmcid: 3918540
Landgren O, Siegel D, Kazandjian D, Costa L, Jakubowiak A. Treatments for newly diagnosed multiple myeloma: when endurance is interrupted. Lancet Oncol. 2020;21(12):e540. https://doi.org/10.1016/S1470-2045(20)30635-5 .
doi: 10.1016/S1470-2045(20)30635-5
pubmed: 33271097
Attal M, Lauwers-Cances V, Hulin C, et al. Lenalidomide, bortezomib, and dexamethasone with transplantation for myeloma. N Engl J Med. 2017;376(14):1311–20. https://doi.org/10.1056/NEJMoa1611750 .
doi: 10.1056/NEJMoa1611750
pubmed: 28379796
pmcid: 6201242
Sidiqi MH, Aljama MA, Bin Riaz I, et al. Bortezomib, lenalidomide, and dexamethasone (VRd) followed by autologous stem cell transplant for multiple myeloma. Blood Cancer J. 2018;8(11):106. https://doi.org/10.1038/s41408-018-0147-7 .
doi: 10.1038/s41408-018-0147-7
pubmed: 30409963
pmcid: 6224498
Devarakonda S, Efebera Y, Sharma N. Role of stem cell transplantation in multiple myeloma. Cancers. 2021;13(4):863. https://doi.org/10.3390/cancers13040863 .
doi: 10.3390/cancers13040863
pubmed: 33670709
pmcid: 7922596
Ntanasis-Stathopoulos I, Gavriatopoulou M, Kastritis E, Terpos E, Dimopoulos MA. Multiple myeloma: role of autologous transplantation. Cancer Treat Rev. 2020;82:101929. https://doi.org/10.1016/j.ctrv.2019.101929 .
doi: 10.1016/j.ctrv.2019.101929
pubmed: 31770695
Martinez-Lopez J, Blade J, Mateos MV, et al. Long-term prognostic significance of response in multiple myeloma after stem cell transplantation. J Am Soc Hematol Blood. 2011;118(3):529–34. https://doi.org/10.1182/blood-2011-01-332320 .
doi: 10.1182/blood-2011-01-332320
O’Gorman P, Laubach JP, O’Dwyer ME, et al. Phase 2 studies of lenalidomide, subcutaneous bortezomib, and dexamethasone as induction therapy in patients with newly diagnosed multiple myeloma. Am J Hematol. 2022;97(5):562–73. https://doi.org/10.1002/ajh.26491 .
doi: 10.1002/ajh.26491
pubmed: 35132679
Sonneveld P, Dimopoulos MA, Boccadoro M, et al. Daratumumab, bortezomib, lenalidomide, and dexamethasone for multiple myeloma[J]. N Engl J Med. 2024;390(4):301–13. https://doi.org/10.1056/NEJMoa2312054 .
doi: 10.1056/NEJMoa2312054
pubmed: 38084760
Voorhees PM, Kaufman JL, Laubach J, et al. Daratumumab, lenalidomide, bortezomib, and dexamethasone for transplant-eligible newly diagnosed multiple myeloma: the GRIFFIN trial[J]. Blood J Am Soc Hematol. 2020;136(8):936–45. https://doi.org/10.1182/blood.2020005288 .
doi: 10.1182/blood.2020005288
Facon T, Cook G, Usmani SZ, et al. Daratumumab plus Lenalidomide and dexamethasone in transplant-ineligible newly diagnosed multiple myeloma: frailty subgroup analysis of MAIA[J]. Leukemia. 2022;36(4):1066–77. https://doi.org/10.1038/s41375-021-01488-8 .
doi: 10.1038/s41375-021-01488-8
pubmed: 34974527
pmcid: 8979809
Facon T, Dimopoulos MA, Leleu XP, et al. Isatuximab, Bortezomib, Lenalidomide, and Dexamethasone for multiple myeloma. NEW ENGL J MED. 2024. https://doi.org/10.1056/NEJMoa2400712 .
doi: 10.1056/NEJMoa2400712
pubmed: 38832972